Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013 - PubMed (original) (raw)
. 2016 Aug;59(8):1692-701.
doi: 10.1007/s00125-016-3971-y. Epub 2016 May 18.
Affiliations
- PMID: 27189067
- DOI: 10.1007/s00125-016-3971-y
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013
Anna Norhammar et al. Diabetologia. 2016 Aug.
Abstract
Aims/hypothesis: The global diabetes epidemic affects countries differently. We aimed to describe trends in the incidence and prevalence of type 2 diabetes mellitus requiring glucose-lowering treatment, together with associated life expectancy and risks of significant clinical complications.
Methods: Data on patients with type 2 diabetes who filled a prescription for any glucose-lowering drug (GLD) during the period 2006-2013 were extracted from the Swedish Prescribed Drug Register, Cause of Death Register and Swedish National Patient Register.
Results: In 2013, the prevalence of GLD-treated type 2 diabetes was 4.4% (n = 352,436) and the incidence was 399 per 100,000 population (n = 30,620). During 2006-2013, the prevalence increased by 61% while the incidence remained relatively stable; the prevalence of cardiovascular disease (CVD, 34% in 2013) and microvascular disease (16% in 2013) was also stable. Insulin use increased by 29% while sulfonylurea use declined by 55%. Compared with the general population, patients with type 2 diabetes had increased risk of myocardial infarction, stroke and all-cause mortality, with age-standardised risks of ∼1.7-, 1.5- and 1.3-fold, respectively. These risks declined over time. Life-years lost due to diabetes was most pronounced at younger ages and improved in women over time from 2006 to 2013.
Conclusions/interpretation: The prevalence of type 2 diabetes requiring GLD treatment in Sweden increased substantially in recent years, while the incidence remained stable. Use of sulfonylurea declined while insulin use increased. The high prevalence of diabetes-related comorbidities, increased risk of complications and life-years lost highlights the need for optimised and new preventive strategies in patients with type 2 diabetes.
Keywords: Cardiovascular disease; Glucose-lowering therapy; Incidence; Life expectancy; Mortality; Prevalence; Type 2 diabetes.
Similar articles
- Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N, Svensson AM, Miftaraj M, Franzén S, Zethelius B, Eliasson B, Gudbjörnsdottir S. Ekström N, et al. Diabetes Obes Metab. 2016 Oct;18(10):990-8. doi: 10.1111/dom.12704. Epub 2016 Jul 19. Diabetes Obes Metab. 2016. PMID: 27282621 - Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Schramm TK, et al. Circulation. 2008 Apr 15;117(15):1945-54. doi: 10.1161/CIRCULATIONAHA.107.720847. Epub 2008 Mar 31. Circulation. 2008. PMID: 18378618 - Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S, Achana FA, Gray LJ, Davies MJ, Khunti K. Seidu S, et al. Diabet Med. 2016 Mar;33(3):280-9. doi: 10.1111/dme.12885. Epub 2015 Sep 8. Diabet Med. 2016. PMID: 26282461 Review. - Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N, Ali MK, Narayan KM. Tandon N, et al. Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Am J Cardiovasc Drugs. 2012. PMID: 22217193 Review.
Cited by
- From unwelcome to supportive. Patients' conceptions of being prescribed a glucose-lowering drug at type 2 diabetes diagnosis - a phenomenographic study.
Dalemo S, Carlsson Y, Alsterhag J, Andersson S. Dalemo S, et al. Int J Qual Stud Health Well-being. 2024 Dec;19(1):2389575. doi: 10.1080/17482631.2024.2389575. Epub 2024 Aug 11. Int J Qual Stud Health Well-being. 2024. PMID: 39129309 Free PMC article. Review. - The effect of non-insulin-based insulin resistance indices on the prediction of recurrence in patients with atrial fibrillation undergoing radiofrequency catheter ablation.
Luo Y, Luo D, Yang G, Huang W, Tang Y, Xu B, He G, Yang Y, He J, Sun H, Cai L, Zhang Z, Liu H, Xiong S. Luo Y, et al. Cardiovasc Diabetol. 2024 Aug 7;23(1):291. doi: 10.1186/s12933-024-02388-8. Cardiovasc Diabetol. 2024. PMID: 39113032 Free PMC article. - Type 2 Diabetes and Fracture Risk in Older Women.
Zoulakis M, Johansson L, Litsne H, Axelsson K, Lorentzon M. Zoulakis M, et al. JAMA Netw Open. 2024 Aug 1;7(8):e2425106. doi: 10.1001/jamanetworkopen.2024.25106. JAMA Netw Open. 2024. PMID: 39106069 Free PMC article. - Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: "INSIST" study.
Mohammedi K, Fauchier L, Quignot N, Khachatryan A, Banon T, Kapnang R, Kikuchi K, Ren H, Massien C, Vigié L, Larsen S, Sibon I. Mohammedi K, et al. Cardiovasc Diabetol. 2024 May 29;23(1):183. doi: 10.1186/s12933-024-02257-4. Cardiovasc Diabetol. 2024. PMID: 38812009 Free PMC article. - Mortality of type 2 diabetes in Germany: additional insights from Gompertz models.
Kuss O, Baumert J, Schmidt C, Tönnies T. Kuss O, et al. Acta Diabetol. 2024 Jun;61(6):765-771. doi: 10.1007/s00592-024-02237-w. Epub 2024 Mar 11. Acta Diabetol. 2024. PMID: 38466430 Free PMC article.
References
- Diabet Med. 2015 Oct;32(10):1319-28 - PubMed
- Diabet Med. 2012 Mar;29(3):385-92 - PubMed
- Diabetologia. 2013 Dec;56(12 ):2601-8 - PubMed
- Diabetes Care. 1999 May;22(5):773-8 - PubMed
- Curr Cardiovasc Risk Rep. 2015;9(7):36 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical